AFA-281

DRUG3 trials

Sponsors

Afasci Inc

Conditions

Alcohol AbuseAlcohol Abuse/addictionAnxietyDepression DisordersLumbosacral RadiculopathyPain ThresholdPain, InflammatoryPain, Neuropathic

Phase 1

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

CompletedNCT05547503

Afasci IncPain, Inflammatory, Pain, Neuropathic

Start: 2023-04-11End: 2025-05-14Updated: 2025-10-21

Phase 2

Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain

Not yet recruitingNCT06649747

Afasci IncLumbosacral Radiculopathy

Start: 2027-04-01End: 2032-03-31Target: 408Updated: 2025-06-26

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Not yet recruitingNCT06710431

Afasci IncAlcohol Abuse, Alcohol Abuse/addiction, Anxiety +3

Start: 2025-10-01End: 2027-12-01Target: 36Updated: 2024-11-29